Synnovation’s PI3Kα inhibitor portfolio draws Novartis in $3B deal
· bioworld
AI Briefing
- Novartis commits $3B to Synnovation's PI3Kα inhibitor portfolio
- Deal to support development of cancer treatments
- Deal is largest ever for a private biotech company
Advertisement